ENDRA Life Sciences Inc.

NasdaqCM:NDRA Stock Report

Market Cap: US$4.1m

ENDRA Life Sciences Balance Sheet Health

Financial Health criteria checks 5/6

ENDRA Life Sciences tiene unos fondos propios totales de $5.2M y una deuda total de $243.1K, lo que sitúa su ratio deuda/fondos propios en 4.7%. Sus activos y pasivos totales son $7.6M y $2.4M respectivamente.

Key information

0.5%

Debt to equity ratio

US$28.48k

Debt

Interest coverage ration/a
CashUS$2.83m
EquityUS$5.66m
Total liabilitiesUS$1.10m
Total assetsUS$6.75m

Recent financial health updates

Recent updates

ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks

Sep 29

ENDRA Life Sciences receives European patent for TAEUS system

Aug 24

Endra Life Sciences Q2 2022 Earnings Preview

Aug 12

We're A Little Worried About ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate

Aug 08
We're A Little Worried About ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate

We're Keeping An Eye On ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate

Nov 18
We're Keeping An Eye On ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate

We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully

Jul 19
We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully

ENDRA Life Sciences names Irina Pestrikova Principal Financial Officer

Jun 15

ENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technology

Jan 13

ENDRA Life Sciences renews GE Healthcare collaboration agreement

Dec 21

Endra Life prices $5M-share offering

Dec 16

Endra Life Sciences EPS beats by $0.02

Nov 16

Financial Position Analysis

Pasivos a corto plazo: NDRALos activos a corto plazo ($6.4M) de la empresa superan a sus pasivos a corto plazo ($2.2M).

Pasivo a largo plazo: NDRALos activos a corto plazo ($6.4M) superan a sus pasivos a largo plazo ($237.2K).


Debt to Equity History and Analysis

Nivel de deuda: NDRA tiene más efectivo que su deuda total.

Reducción de la deuda: NDRAha pasado de 0.4% a 0.5% en los últimos 5 años.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Cash runway estable: NDRA tiene suficiente cash runway para 4 meses según el último flujo de caja libre declarado [flujo de caja libre]], pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: NDRA se prevé que disponga de suficiente liquidez para 4 meses según las estimaciones de flujo de caja libre, pero desde entonces ha obtenido capital adicional.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.